Literature DB >> 19714583

Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis.

Wilco de Jager1, Sebastiaan J Vastert, Jeffrey M Beekman, Nico M Wulffraat, Wietse Kuis, Paul J Coffer, Berent J Prakken.   

Abstract

OBJECTIVE: Systemic-onset juvenile idiopathic arthritis (JIA) is an autoimmune disease characterized by arthritis and systemic features. Its pathogenesis is still largely unknown. It is characterized immunologically by natural killer (NK) cell dysfunction and cytokine signatures that predominantly feature interleukin-1 (IL-1), IL-6, and IL-18. Since IL-18 can drive NK cell function, we examined how the high plasma levels of this cytokine are related to the documented NK cell failure in these patients.
METHODS: The phenotype and function of NK cells from 10 healthy control subjects, 15 patients with polyarticular JIA, and 15 patients with systemic-onset JIA were characterized by staining and functional assays in vitro. IL-18 ligand binding was visualized by fluorescence microscopy. Phosphorylation of several MAP kinases and the IL-18 receptor beta (IL-18Rbeta) were visualized by Western blotting.
RESULTS: IL-18 from the plasma of systemic-onset JIA patients stimulated the activation of NK cells from healthy controls and bound its cognate receptor. However, NK cells from systemic-onset JIA patients failed to up-regulate cell-mediated killing molecules, such as perforin and interferon-gamma, after IL-18 stimulation. Furthermore, treatment with IL-18 did not induce the phosphorylation of receptor-activated MAP kinases in NK cells. Alternate activation of NK cells by IL-12 induced NK cell cytotoxicity. We observed no additive effect of IL-18 in combination with IL-12 in systemic-onset JIA patients. Immunoprecipitation of IL-18Rbeta showed that NK cells from systemic-onset JIA could not phosphorylate this receptor after IL-18 stimulation.
CONCLUSION: The mechanism of the impaired NK cell function in systemic-onset JIA involves a defect in IL-18Rbeta phosphorylation. This observation has major implications for the understanding and, ultimately, the treatment of systemic-onset JIA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19714583     DOI: 10.1002/art.24750

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  39 in total

Review 1.  What do cytokine profiles tell us about subsets of juvenile idiopathic arthritis?

Authors:  Rolando Cimaz; Davide Moretti; Ilaria Pagnini; Achille Marino; Luca Cantarini; Gabriele Simonini
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

2.  Signalling in the genomic era.

Authors:  Vincenza Rita Lo Vasco
Journal:  J Cell Commun Signal       Date:  2010-06-06       Impact factor: 5.782

3.  Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect.

Authors:  Julien Carvelli; Christelle Piperoglou; Catherine Farnarier; Frédéric Vely; Karin Mazodier; Sandra Audonnet; Patrick Nitschke; Christine Bole-Feysot; Mohamed Boucekine; Audrey Cambon; Mohamed Hamidou; Jean-Robert Harle; Geneviève de Saint Basile; Gilles Kaplanski
Journal:  Blood       Date:  2020-07-30       Impact factor: 22.113

4.  Paediatric rheumatic disease: Diagnosing macrophage activation syndrome in systemic JIA.

Authors:  Sebastiaan J Vastert; Berent J Prakken
Journal:  Nat Rev Rheumatol       Date:  2014-09-09       Impact factor: 20.543

Review 5.  [Still's disease in children and adults].

Authors:  C M Hedrich; C Günther; M Aringer
Journal:  Z Rheumatol       Date:  2017-09       Impact factor: 1.372

6.  Candidate's single-nucleotide polymorphism predictors of treatment nonresponse to the first anti-TNF inhibitor in ankylosing spondylitis.

Authors:  Ruxandra Schiotis; Alejandra Sánchez; Alejandro Escudero; Nerea Bartolomé; Magdalena Szczypiorska; Pilar Font; Antonio Martínez; Diego Tejedor; Marta Artieda; Juan Mulero; Anca Buzoianu; Eduardo Collantes-Estévez
Journal:  Rheumatol Int       Date:  2013-12-15       Impact factor: 2.631

7.  Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition.

Authors:  Scott W Canna; Charlotte Girard; Louise Malle; Adriana de Jesus; Neil Romberg; Judith Kelsen; Lea F Surrey; Pierre Russo; Andrew Sleight; Eduardo Schiffrin; Cem Gabay; Raphaela Goldbach-Mansky; Edward M Behrens
Journal:  J Allergy Clin Immunol       Date:  2016-11-19       Impact factor: 10.793

Review 8.  Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.

Authors:  Elizabeth D Mellins; Claudia Macaubas; Alexei A Grom
Journal:  Nat Rev Rheumatol       Date:  2011-06-07       Impact factor: 20.543

9.  Role of cytolytic impairment of natural killer and natural killer T-cell populations in rheumatoid arthritis.

Authors:  Ashish Aggarwal; Aman Sharma; Archana Bhatnagar
Journal:  Clin Rheumatol       Date:  2014-05-07       Impact factor: 2.980

Review 10.  Tocilizumab in pediatric rheumatology: the clinical experience.

Authors:  Reut Gurion; Nora G Singer
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.